Research programme: oral T-cell vaccines - VAXIMM

Drug Profile

Research programme: oral T-cell vaccines - VAXIMM

Alternative Names: VXM 04; VXM 06; VXM 10m; VXM 10ma

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VAXIMM
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Angiogenesis inhibitors; CD274 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR - 2017)
  • 01 Apr 2017 Pharmacodynamic, adverse events and immunogenicity data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 01 Dec 2016 Preclinical development is ongoing Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top